Cenobamato｜Apilepsy｜HongKong DengYue Medicine

Cenobamato Application Scope

Cenobamato is indicated for the treatment of partial-onset seizures in adult patients.

Cenobamato Characteristics

• Ingredients: Active ingredient: Cenobamato.​

• Properties: Cenobamato is a novel antiepileptic drug that acts by blocking voltage-gated sodium channels and enhancing GABAergic neurotransmission, thereby reducing neuronal excitability.

• Specification: Available in tablet form with strengths of 12.5 mg, 25 mg, 50 mg, 100 mg, and 200 mg.​

• Packaging Specification: Supplied in blister packs or bottles, depending on the dosage and quantity.​

• Storage: Store at room temperature, between 20°C to 25°C (68°F to 77°F).​

• Expiry Date: Refer to the packaging for the specific expiration date.​

• Executive Standard: Approved by the U.S. Food and Drug Administration (FDA) under NDA 212839.

• Approval Number: NDA 212839.

• Date of Revision: Refer to the latest prescribing information for the most recent revision date.​

• Manufacturer: SK Life Science, Inc.​

Guidelines For The Use Of Cenobamato

• Dosage and Administration:

  • Initiate treatment at 12.5 mg once daily.​

  • Titrate the dose every two weeks as follows:​

    • Week 1–2: 12.5 mg once daily

    • Week 3–4: 25 mg once daily

    • Week 5–6: 50 mg once daily

    • Week 7–8: 100 mg once daily

    • Week 9–10: 150 mg once daily

    • Week 11 and thereafter: 200 mg once daily

  • If needed, the dose may be increased above 200 mg by increments of 50 mg once daily every two weeks to a maximum of 400 mg once daily, based on clinical response and tolerability.

• Adverse Reactions:

  • Common adverse reactions include somnolence, dizziness, fatigue, diplopia, and headache.​

  • Serious adverse reactions may include Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).

• Contraindications:

  • Cenobamato is contraindicated in patients with familial short QT syndrome.

• Precautions:

  • Use caution in patients with hepatic or renal impairment.​

  • Monitor for signs of hypersensitivity reactions.​

  • Advise patients to avoid operating machinery or driving until they know how Cenobamato affects them.​

Cenobamato Interactions

• Drug Interactions:

  • Cenobamato may decrease the effectiveness of hormonal contraceptives; alternative non-hormonal contraceptive methods are recommended.​

  • May increase plasma concentrations of phenytoin and phenobarbital; dose adjustments may be necessary.

  • May decrease plasma concentrations of drugs metabolized by CYP3A4 and CYP2B6 (e.g., midazolam, bupropion).​

  • May increase plasma concentrations of drugs metabolized by CYP2C19 (e.g., omeprazole).

 

Note:

• If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
• It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.